ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CERE Cerevel Therapeutics Holdings Inc

41.47
-0.065 (-0.16%)
Jun 17 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 993,891
Bid Price 41.00
Ask Price 42.70
News -
Day High 41.66

Low
19.59

52 Week Range

High
43.5898

Day Low 41.395
Share Name Share Symbol Market Stock Type
Cerevel Therapeutics Holdings Inc CERE NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.065 -0.16% 41.47 19:00:00
Open Price Low Price High Price Close Price Previous Close
41.53 41.395 41.66 41.47 41.535
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
8,467 993,891 US$ 41.52 US$ 41,267,751 - 19.59 - 43.5898
Last Trade Type Quantity Price Currency
16:31:40 priorref 122,400 US$ 41.47 USD

Cerevel Therapeutics (CERE) Options Flow Summary

Overall Flow

Bullish

Net Premium

55k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

Cerevel Therapeutics Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.83B 181.58M - 0 -432.84M -2.38 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Cerevel Therapeutics News

Date Time Source News Article
5/08/202415:17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
4/18/202405:30GlobeNewswire Inc.Cerevel Therapeutics Announces Positive Topline Results for..
2/27/202415:02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2/16/202415:46Edgar (US Regulatory)Form 8-K - Current report
2/09/202408:00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting..
2/08/202418:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
1/24/202407:30PR Newswire (US)Kuehn Law Encourages MDC, WAVD, NS and CERE Investors to..
1/23/202416:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
1/23/202416:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
1/23/202416:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
1/23/202416:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
1/23/202416:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CERE Message Board. Create One! See More Posts on CERE Message Board See More Message Board Posts

Historical CERE Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week40.0241.85539.9541.021,662,8631.453.62%
1 Month42.1642.1939.9341.031,326,314-0.69-1.64%
3 Months42.2042.8839.9341.751,150,287-0.73-1.73%
6 Months41.2243.589839.9341.911,426,0840.250.61%
1 Year33.8643.589819.5936.971,451,8047.6122.47%
3 Years13.4646.160812.0132.761,009,04828.01208.10%
5 Years10.4546.16089.0031.73882,26231.02296.84%

Cerevel Therapeutics Description

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Your Recent History

Delayed Upgrade Clock